Today: 7 February 2026
Subscribe
Browse Category

Pharma Industry News 8 January 2026 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

New York, January 14, 2026, 14:54 EST — During regular session Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40. The move came after Praxis announced late Tuesday it hired epilepsy expert Dr. Orrin Devinsky for a new head of clinical strategy role. Steven Petrou, president of research and development, said Devinsky’s choice to join “reflects the strength of our scientific approach and long-term strategy.” (GlobeNewswire) Timing is crucial since investors zero in on regulatory filings that can shift a
14 January 2026
····
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

New York, January 14, 2026, 13:09 EST — Regular session underway. Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity treatments. CEO Brian Lian noted that interest was “broader than is visible” with more players “circling around the space.” Analysts put the potential market at $150 billion annually, and Pfizer’s $10 billion acquisition of Metsera last November has kept deal activity intense. (Reuters) The timing is key. The J.P. Morgan Healthcare Conference, an annual hotspot for merger chatter and biotech
14 January 2026
····
Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle

Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle

New York, Jan 14, 2026, 12:49 ET — Regular session Shares of Thermo Fisher Scientific (NYSE: TMO) climbed 1.4% to $615.46 Wednesday after CEO Marc Casper announced that the company’s pharma services division secured contracts linked to “reshoring” — shifting drug manufacturing back from Europe and Asia to the U.S. Speaking at the J.P. Morgan Healthcare Conference, Casper highlighted “a very big focus on reshoring” and noted that a delayed proposed 100% tariff on imported medicines has already prompted customers to accelerate projects and reconsider pricing. Evercore ISI analyst Vijay Kumar described the outlook as “constructive.” Casper also referenced Thermo’s
14 January 2026
·····
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

NEW YORK, Jan 13, 2026, 16:19 EST — After-hours Shares of Harmony Biosciences Holdings Inc (HRMY) slid 6.4% on Tuesday to close at $35.82, after trading as low as $34.69. The move comes as investors work through a pipeline reshuffle and a new revenue outlook that landed just as healthcare executives crowd into San Francisco for the annual J.P. Morgan conference. Harmony’s stock tends to move on two things: what Wakix can do next, and whether the company can build something that matters beyond it. Tuesday’s update hit both levers, in opposite directions. Harmony said preliminary, unaudited net product revenue
13 January 2026
·····
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might impact big pharma in 2026 — and if Washington’s efforts will become a serious drag on margins or just a tolerable hit. It also brings trade policy into the pricing debate, a spot few shareholders anticipated focusing on this early
13 January 2026
·····
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

New York, Jan 13, 2026, 10:45 (EST) — Regular session ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session. The move matters because ImmunityBio is trying to widen the case for ANKTIVA beyond its current franchise, and lung cancer is where drug makers chase scale. Traders have been quick to react to any read-through on whether the company can turn trial data into a clearer path for new use cases. In a
13 January 2026
·····
Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

New York, Jan 12, 2026, 14:41 EST — Regular session Apellis Pharmaceuticals shares dropped almost 15% Monday following the release of preliminary 2025 U.S. sales numbers ahead of its J.P. Morgan Healthcare Conference update. The move put the stock in focus as biotech firms roll out early guidance for the year. Timing is key. The J.P. Morgan meeting tends to trigger sharp, single-day swings as investors reassess everything from product demand to cash burn ahead of the busy earnings season. Apellis is working to bolster confidence in SYFOVRE, its treatment for geographic atrophy, while validating early sales momentum for EMPAVELI
12 January 2026
·····
Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

New York, January 12, 2026, 09:55 EST — Regular session Moderna (MRNA.O) shares dropped about 2% to $33.60 early Monday after the biotech forecasted around $1.9 billion in revenue for 2025 and lowered its GAAP operating-expense forecast for that year—the U.S. accounting standard. The stock swung between $35.77 and $33.33 in a volatile session. (ACCESS Newswire) This update is crucial as Moderna strives to reassure investors it can sustain itself on seasonal vaccine revenues and an expanding pipeline, rather than relying on pandemic-era demand. Traders are fixated on cash levels and how quickly the company is cutting expenses. The timing
12 January 2026
·····
AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

New York, January 11, 2026, 11:10 EST — Market closed AbbVie Inc. (ABBV.N) closed Friday down 1.8% at $220.08. As U.S. markets remain closed over the weekend, chatter about a potential deal lingers heading into Monday. The J.P. Morgan Healthcare Conference week draws attention now, serving as a hotspot for new guidance, pipeline updates, and those crucial side-room talks that often spark M&A activity. For major drugmakers, it’s also the moment investors demand a clear answer: should they buy growth or build it themselves? Deal advisers told Reuters they expect a surge in large healthcare M&A deals in 2026 as
11 January 2026
····
AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next

AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next

New York, January 10, 2026, 14:04 EST — Market closed AstraZeneca PLC’s U.S.-listed shares will exit the Nasdaq-100 on Jan. 20, with Walmart stepping in as its replacement, Nasdaq announced Friday. Walmart revealed in November plans to shift its listing from the New York Stock Exchange to Nasdaq. (Reuters) This matters since the Nasdaq-100 is closely followed by index funds and ETFs that trade stocks just to match the benchmark. When a stock falls out, those funds usually have to trim their positions, no matter what’s going on with the company itself. AstraZeneca faces a calendar-driven trade layered onto its
10 January 2026
······
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

New York, Jan 9, 2026, 15:46 EST — Regular session Arcutis Biotherapeutics shares slid 5.3% to $28.29 in afternoon trading on Friday, after climbing as high as $30.70 earlier. The stock was last at the session low. The move followed a cooler U.S. payrolls report, which reinforced expectations the Federal Reserve will keep rates steady in coming weeks. High-growth biotech names can swing hard when the rate outlook gets murkier. (Reuters) Broader biotech held up better. The S&P biotech ETF XBI and the iShares Nasdaq Biotechnology ETF IBB were both higher, tracking gains in the S&P 500 and Nasdaq-100 ETFs.
9 January 2026
·····
Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

New York, Jan 8, 2026, 05:22 EST — Premarket Shares of Revolution Medicines fell 9.8% to $92.60 in premarket trading on Thursday, pulling back after a sharp, rumor-driven run-up in the prior session. Investing.com The whipsaw started after the Wall Street Journal reported AbbVie was in advanced discussions to buy the cancer-drug developer, a deal that could value Revolution at about $20 billion, including a typical takeover premium — the extra paid above the market price. The Journal also said other bidders could be in the mix. The Wall Street Journal AbbVie later said it was not in discussions with
8 January 2026
···
1 2 3 4 … 9

Stock Market Today

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

7 February 2026
Macquarie Group shares fell 2.17% to A$207.83 Friday, marking a third straight decline as the ASX 200 slid 2%. Australia’s regulator trimmed liquidity requirements for Macquarie Bank after improvements in controls. Macquarie Asset Management announced two UK utility deals, including full ownership of Last Mile Infrastructure and the purchase of Energy Assets Group. Investors await Tuesday’s operational briefing.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:06 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Go toTop